日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer

Gemogenovatucel-T 在克隆性肿瘤突变负荷高卵巢癌中的优势

Coleman, Robert L; Rocconi, Rodney; Monk, Bradley J; Walter, Adam; Stanbery, Laura; Willoughby, David; Nagel, Casey; Wei, Qi; Wallraven, Gladice; Horvath, Staci; Tang, Min; Rao, Donald; Bognar, Ernest; Nemunaitis, John

Preclinical assessment of GNE(wt)/bi-shRNA-GNE(M743T) lipoplex product development for GNE myopathy

GNE(wt)/bi-shRNA-GNE(M743T)脂质体复合物产品开发治疗GNE肌病的临床前评估

Kerneis, Fabienne; Jay, Christopher M; Rao, Donald; Winchester, Jeremy; Nemunaitis, Alexander; Nemunaitis, Emily; Bognar, Ernest; Wallraven, Gladice; Stanbery, Laura; Walter, Adam; Sarshar, Sep; Nemunaitis, John

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

外显子组测序显示,自体肿瘤和Vigil产品之间克隆性肿瘤突变负荷、肿瘤内异质性和克隆性新抗原的模式相同。

Willoughby, David; Bognar, Ernest; Stanbery, Laura; Nagel, Casey; Wallraven, Gladice; Pruthi, Aman; Bild, Nicholas; Stamper, Ericca; Rao, Donald; Walter, Adam; Nemunaitis, John

Clinical characterization and therapeutic targeting of fusion genes in oncology

肿瘤融合基因的临床特征及治疗靶向

Morand, Susan; Rager, Lauren; Craig, Daniel; Nemunaitis, Alexander; Choucair, Khalil; Rao, Donald; Stanbery, Laura; Phinney, Richard C; Walter, Adam; Ghisoli, Maurizio; Nemunaitis, John

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer

聚(ADP-核糖)聚合酶抑制剂与免疫检查点抑制剂的靶向联合治疗缺乏疗效证据:聚焦卵巢癌

Bailey, Morgan; Morand, Susan; Royfman, Rachel; Lin, Leslie; Singh, Aditi; Stanbery, Laura; Walter, Adam; Hamouda, Danae; Nemunaitis, John

3D engineered scaffold for large-scale Vigil immunotherapy production

用于大规模生产 Vigil 免疫疗法的 3D 工程支架

Fabienne Kerneis, Ernest Bognar, Laura Stanbery, Seongjun Moon, Do Hoon Kim, Yuxuan Deng, Elliot Hughes, Tae-Hwa Chun, Darron Tharp, Heidi Zupanc, Chris Jay, Adam Walter, John Nemunaitis, Joerg Lahann

Regulatory role of CD39 and CD73 in tumor immunity

CD39和CD73在肿瘤免疫中的调控作用

Kaplinsky, Nicole; Williams, Kada; Watkins, Dean; Adams, Molly; Stanbery, Laura; Nemunaitis, John

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy

Gemogenovatucel-T(Vigil):基于双shRNA质粒的靶向免疫疗法

Nemunaitis, John; Stanbery, Laura; Walter, Adam; Wallraven, Gladice; Nemunaitis, Alexander; Horvath, Staci; Bognar, Ernest; Rao, Donald; Engle, Steven; Brun, Scott; Ghisoli, Maurizio; Rocconi, Rodney P; Monk, Bradley J; Coleman, Robert L

Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

采用维吉拉/替莫唑胺/伊立替康治疗复发性尤文氏肉瘤并评估循环肿瘤(ct)DNA的初步研究

Anderson, Peter; Ghisoli, Maurizio; Crompton, Brian D; Klega, Kelly S; Wexler, Leonard H; Slotkin, Emily K; Stanbery, Laura; Manning, Luisa; Wallraven, Gladice; Manley, Meghan; Horvath, Staci; Bognar, Ernest; Nemunaitis, John

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer

利用同源重组功能正常的分子谱作为卵巢癌治疗靶向生物标志物的理由

Nemunaitis, John; Stanbery, Laura; Walter, Adam; Rocconi, Rodney; Stephens, Philip